National Institute for Health and Care Excellence (NICE) recommends Jardiance®▼(empagliflozin) for the treatment of Type 2 Diabetes (T2D) to improve glycaemic control in adults

BRACKNELL, England--(BUSINESS WIRE)--The Boehringer Ingelheim and Eli Lilly Diabetes Alliance announced today that the National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Determination¹ (FAD) recommending Jardiance (empagliflozin) for use within the National Health Service (NHS England) in the treatment of type 2 diabetes as follows:-

1.1 Empagliflozin in a dual therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if:

• a sulfonylurea is contraindicated or not tolerated, or
• the person is at significant risk of hypoglycaemia or its consequences.

1.2 Empagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in combination with:

• metformin and a sulfonylurea or
• metformin and a thiazolidinedione.

1.3 Empagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an option for treating type 2 diabetes.

1.4 People currently receiving treatment initiated within the NHS with empagliflozin that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

An estimated 2,974,950 adults (20-79 years) in the United Kingdom have Type 1 or Type 2 Diabetes². T2D is the most common type, accounting for an estimated 90% of all diabetes cases³. Although a range of treatments exist to manage the condition, only 64.8% of people hit the NICE glycaemic target of 7.5%⁴.

“We are very pleased that NICE has recommended empagliflozin as a clinically and cost effective treatment. It will provide an additional therapeutic option for the management of glycaemic control in people with type 2 diabetes in England” said Dr Charles De Wet, Medical Director Boehringer Ingelheim Ltd UK.

~Ends~

NOTES TO EDITORS

About Empagliflozin

Empagliflozin, marketed in Europe as Jardiance^®5 is an oral, once daily tablet for the treatment of adults with Type 2 Diabetes and is part of the SGLT2 inhibitor class. SGLT2 are proteins fundamental to the kidney’s role in filtering blood sugar and are responsible for about 90 percent of the reabsorption of glucose back into the bloodstream.⁶ In people with T2D, there is an overexpression of SGLT2, contributing to elevated blood glucose levels.⁷

Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centres on three compounds representing several of the largest treatment classes. This alliance leverages the companies’ strengths as two of the world’s leading pharmaceutical companies, combining Boehringer Ingelheim’s solid track record of research-driven innovation and Lilly’s innovative research, experience, and pioneering history in diabetes. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Find out more about the alliance at www.boehringer-ingelheim.co.uk or www.lilly.co.uk

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euro, of which 19.5% of the net sales from our Prescription Medicine business is invested into research and development.

For more information please visit www.boehringer-ingelheim.co.uk.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.co.uk.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.co.uk.

###

References

1 Jardiance^® (empagliflozin) NICE recommendation www.nice.org.uk/guidance/indevelopment/gid-tag441/documents.
last accessed 22nd January 2015

2 International Diabetes Federation. IDF Diabetes Atlas 6th Edition, Brussels, 2013.

3 NICE pathways report, Blood glucose lowering therapy for type 2 diabetes, 2014
http://pathways.nice.org.uk/pathways/diabetes last accessed 16th January 2015

4 Health and Social Care Information Centre National Diabetes Audit, 2012-13
http://www.hsic.gov.uk/catalogue/PUB14970 last accessed 16th Jan 2015

5 Jardiance^® (empagliflozin) Summary of Product Characteristics.
10mg https://www.medicines.org.uk/emc/medicine/28973 last accessed 16th January 2015
25mg https://www.medicines.org.uk/emc/medicine/28974 last accessed 16th January 2015

6 Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009;25(3):671-81.

7 Poudel RR. Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition. Indian J Endocrinol Metab. 2013;17(4):588-93.